Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Rhea-AI Summary
Amneal (Nasdaq: AMRX) announced positive interim Phase 4 ELEVATE-PD results (first 111 patients, six weeks) showing clinically meaningful benefits after switching to CREXONT. Patients switching from RYTARY gained +3.07 hours daily “Good On” time and nearly doubled continuous “Good On” intervals to 6.58 hours.
Across prior therapies CREXONT increased “Good On” time, reduced “Off” time, and improved MDS-UPDRS scores; common adverse events included dizziness and nausea.
Positive
- RYTARY switch: +3.07 hours daily Good On time
- Continuous Good On interval nearly +3.09 hours
- MDS-UPDRS improvements of –10 to –15.3 points
- Reduced Off time by ~3 hours across cohorts
Negative
- Most common TEAEs include dizziness 9.0% and nausea 7.2%
- Falls 7.2% reported among study participants
- Small RYTARY subgroup size: n=22 limits precision
News Market Reaction – AMRX
On the day this news was published, AMRX declined 4.67%, reflecting a moderate negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $206M from the company's valuation, bringing the market cap to $4.21B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMRX gained 6.26%, while key peers like PBH (+0.76%), INDV (+1.30%), HCM (+0.90%), and PRGO (+1.37%) saw only modest moves, and BHC was flat. The stronger AMRX move suggests a stock-specific reaction to the CREXONT Phase 4 data rather than a broad sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | ELEVATE-PD interim data | Positive | +2.0% | First 55-patient interim ELEVATE-PD readout showed improved Good On and Off times. |
| Jun 25 | Biosimilar Phase 3 topline | Positive | -1.0% | Phase 3 ADL-018 Xolair biosimilar met endpoints with therapeutic equivalence and safety. |
| Apr 07 | CREXONT Phase 3 data | Positive | -2.3% | RISE-PD analysis showed significant sleep quality improvements after switching to CREXONT. |
Clinical-trial news for AMRX has produced mixed stock reactions, with more divergences than alignments between positive data and price moves.
Recent clinical updates show Amneal steadily building a CREXONT and biosimilars franchise. On Apr 7, 2025, Phase 3 RISE-PD data highlighted significant sleep-quality improvements with CREXONT but the stock fell. On Jun 25, 2025, positive Phase 3 biosimilar ADL-018 topline results again saw a modest decline. The Dec 5, 2025 positive interim ELEVATE-PD CREXONT update produced a +2.01% gain. Today’s larger move follows this ongoing pattern of CREXONT-focused efficacy data releases.
Historical Comparison
In the past year, AMRX issued 3 clinical-trial updates averaging a -0.42% move. Today’s +6.26% reaction to expanded ELEVATE-PD data is a notable upside outlier versus prior clinical headlines.
Clinical news has progressed from Phase 3 RISE-PD sleep outcomes, to a Phase 3 biosimilar success, to successive interim ELEVATE-PD CREXONT readouts, building a broader real-world efficacy and safety profile.
Market Pulse Summary
This announcement reinforces CREXONT’s profile with Phase 4 ELEVATE-PD interim data in 111 patients, showing multi-hour gains in daily “Good On” time and reductions in “Off” time across prior therapy groups, including RYTARY. Historically, Amneal’s clinical news has produced mixed stock reactions, so investors may watch for longer-term outcomes, patient-reported measures, and additional 2026 readouts to gauge durability, safety consistency, and real-world uptake implications for CREXONT.
Key Terms
phase 4 medical
muc oadhesive polymer medical
treatment-emergent adverse events medical
TEAEs medical
MDS-UPDRS medical
monoamine oxidase (MAO) inhibitors medical
AI-generated analysis. Not financial advice.
- Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups
- Demonstrated substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function after switching to CREXONT®
- Patients switching to CREXONT® from RYTARY® gained 3.07 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of effective symptom control
BRIDGEWATER, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology (AAN).
The first 111 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT® (carbidopa and levodopa) extended-release capsules, regardless of whether patients switched from immediate-release carbidopa/levodopa (IR CD/LD), IR CD/LD plus a COMT inhibitor, or RYTARY® (carbidopa and levodopa) extended-release capsules. These interim findings build on the established efficacy and safety profile of CREXONT demonstrated in the Phase 3 RISE-PD trial and reflected in the FDA-approved prescribing information.
After patients switched from prior therapies, treatment with CREXONT delivered meaningful increases in “Good On” time, reductions in “Off” time, and improved motor symptom control. Patients switching from RYTARY achieved consistent gains in continuous “Good On” intervals – the length of uninterrupted time patients spend feeling their best. The most common adverse events (≥
“In the absence of a cure for Parkinson’s, our goal as clinicians is to help patients better manage their symptoms and preserve quality of life for as long as possible,” said Dr. Robert Hauser, MD, a study investigator and Professor of Neurology at the Parkinson’s Disease and Movement Disorders Center, University of South Florida. “These encouraging interim results underscore the real-world impact CREXONT can have in giving patients more ‘Good On’ time with fewer dosing interruptions throughout their day-to-day.”
“When we assess what patients value most in their Parkinson’s disease treatment, longer periods of ‘Good On’ time and less burdensome dosing schedules are among the most important priorities,” said Dr. Avinash Desai, Senior Vice President and Chief Scientific Officer, Specialty, at Amneal. “These interim results confirm that CREXONT delivers on that need, giving patients more ‘Good On’ time, reducing motor fluctuations, and providing the kind of consistent, predictable symptom control that can make a real difference in daily life.”
Overall Interim Findings (First 111 Patients, Six-Week Analysis)
Among 111 patients who switched to CREXONT (mean age 67.3±9.58 years):
Increased Daily “Good On” Time:
- +3.40 hours when switching from IR CD/LD (n=74)
- +2.91 hours when switching from IR CD/LD + COMT inhibitor (n=9)
- +3.07 hours when switching from RYTARY (n=22)
Reduced Daily “Off” Time:
- –3.18 hours when switching from IR CD/LD
- –3.09 hours when switching from IR CD/LD + COMT inhibitor
- –2.90 hours when switching from RYTARY
Improved MDS-UPDRS Total Scores
- Improvements of –15.3, –10.0, and –10.3 points when switching from IR CD/LD, IR CD/LD + COMT inhibitor, and RYTARY, respectively — reductions of this magnitude reflect clinically meaningful gains in overall motor function
Subgroup Analysis: Additional Interim Findings in Patients Switching from RYTARY®
Among the 22 patients switching from RYTARY, CREXONT delivered particularly notable gains in symptom control:
- Mean duration of continuous “Good On” intervals nearly doubled, increasing from 3.45 hours at baseline to 6.58 hours at Week 6, a 3.09-hour gain in uninterrupted symptom control
- Mean daily motor fluctuations were meaningfully reduced, decreasing from 4.75 at baseline to 2.79 at Week 6, a 1.92 reduction in daily motor fluctuations
Safety: In the study, treatment-emergent adverse events (TEAEs) were generally mild to moderate and consistent with prior therapy. The most common (≥
CREXONT should not be taken with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors. CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Treatment with carbidopa/levodopa, including CREXONT, may contribute to reduced vitamin B6 levels. Seizures associated with vitamin B6 deficiency have been reported. Evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies.
CREXONT is Amneal’s next-generation extended-release carbidopa/levodopa (CD/LD) formulation that uses a novel mucoadhesive polymer designed to optimize levodopa delivery and absorption, providing the longest-lasting levodopa plasma levels of any oral CD/LD therapy available today.
As ELEVATE-PD continues to enroll, Amneal will present longer-term outcomes and patient-reported results throughout 2026, building a comprehensive body of evidence for CREXONT’s impact on motor symptom control and functional independence for people living with Parkinson’s disease.
About CREXONT®
CREXONT is an innovative formulation consisting of immediate-release granules with carbidopa and levodopa for rapid onset of action and extended-release pellets containing a mucoadhesive polymer technology with a levodopa core for long-lasting efficacy. CREXONT formulation and dosage strengths are different from RYTARY® (carbidopa and levodopa) extended-release capsules approved by the U.S. FDA in 2015. Learn more about CREXONT at crexont.com.
About ELEVATE-PD
ELEVATE-PD is an open-label, Phase 4, multi-center clinical study designed to evaluate the real-world efficacy and safety of switching to CREXONT in adults with Parkinson’s disease experiencing motor complications such as OFF periods and dyskinesia despite being on a stable dose of an oral levodopa-based regimen. The trial plans to enroll approximately 220 participants and will follow them for 13–14 months, consisting of 10 clinical visits.
INDICATION
CREXONT (carbidopa and levodopa) extended-release capsules for oral use is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
IMPORTANT SAFETY INFORMATION
- Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.
- Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.
- CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery, until you know how CREXONT affects you.
- Your doctor should evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies as seizures associated with low levels of vitamin B6 have been reported. Traditional anti-seizure medications were not effective, and seizures were only resolved after vitamin B6 administration.
- Other symptoms of vitamin B6 deficiency include depression, confusion, cracked corners of the mouth, swollen tongue, skin inflammation, low red blood cell count, and/or numbness, tingling, or weakness in the extremities. Your doctor may advise you to take vitamin B6 as necessary.
- The most common side effects that may occur with CREXONT are nausea and anxiety.
- Avoid sudden discontinuation or rapid dose reduction with CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.
- You may take CREXONT with or without food; but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.
- Swallow CREXONT whole. Do not chew, divide, or crush the capsules.
- Do not take CREXONT with alcohol.
Tell your healthcare provider if you:
- Have any heart conditions, especially if you have had a heart attack or irregular heartbeats.
- Experience hallucinations or abnormal thoughts and behaviors.
- Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges.
- Have thoughts of suicide or have attempted suicide.
- Have abnormal involuntary movements that appear or get worse during treatment.
- Have ever had a peptic ulcer or glaucoma.
- Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm.
- Are breastfeeding during therapy.
- Have side effects; your doctor can adjust your dose.
To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please read the full Prescribing Information. For more information talk to your healthcare provider.
About Parkinson’s Disease
Parkinson’s disease (PD) has become the fastest growing neurological disorder worldwide, with approximately 1 million people diagnosed in the U.S. It is a progressive disorder of the central nervous system (CNS) that affects dopamine-producing neurons in the brain that affect movement. PD is characterized by slowness of movement, stiffness, resting tremor and impaired balance. While PD is not considered a fatal disease, it is associated with significant morbidity and disability. The average age at diagnosis for people with PD is 60; as people live longer, the number of people living with PD is predicted to grow significantly over the coming decades.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com
